 Francisco La Rosa
Concepts (437)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 22 | 2022 | 1043 | 2.400 |
Why?
| | Urinary Bladder Neoplasms | 8 | 2024 | 252 | 1.610 |
Why?
| | Prostate | 9 | 2022 | 175 | 1.320 |
Why?
| | Kidney Neoplasms | 10 | 2014 | 403 | 1.040 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 683 | 0.690 |
Why?
| | Prostatectomy | 9 | 2022 | 104 | 0.670 |
Why?
| | Carcinoma, Papillary | 3 | 2015 | 81 | 0.590 |
Why?
| | Adenocarcinoma | 4 | 2014 | 940 | 0.570 |
Why?
| | Solitary Fibrous Tumors | 1 | 2017 | 5 | 0.540 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2015 | 57 | 0.530 |
Why?
| | Carcinoma, Basal Cell | 2 | 2014 | 75 | 0.510 |
Why?
| | Spectrum Analysis | 1 | 2016 | 91 | 0.500 |
Why?
| | Carcinoma, Renal Cell | 3 | 2013 | 217 | 0.490 |
Why?
| | Thyroid Gland | 9 | 2000 | 94 | 0.480 |
Why?
| | Biopsy | 8 | 2019 | 1129 | 0.440 |
Why?
| | Parturition | 1 | 2014 | 71 | 0.430 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2014 | 71 | 0.430 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 8 | 0.420 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 17 | 0.420 |
Why?
| | Biopsy, Needle | 7 | 2016 | 189 | 0.380 |
Why?
| | Neoplasm Grading | 7 | 2022 | 307 | 0.370 |
Why?
| | Seasons | 1 | 2014 | 547 | 0.370 |
Why?
| | Neoplasm Invasiveness | 5 | 2024 | 510 | 0.360 |
Why?
| | Lymph Node Excision | 3 | 2024 | 171 | 0.360 |
Why?
| | Cystectomy | 2 | 2024 | 37 | 0.350 |
Why?
| | Urothelium | 3 | 2015 | 37 | 0.330 |
Why?
| | Neoplasm Staging | 6 | 2024 | 1389 | 0.330 |
Why?
| | Male | 56 | 2025 | 67762 | 0.330 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2021 | 77 | 0.330 |
Why?
| | Skin Neoplasms | 2 | 2014 | 855 | 0.320 |
Why?
| | Cyclic AMP | 7 | 2000 | 234 | 0.310 |
Why?
| | Aged | 22 | 2024 | 23961 | 0.300 |
Why?
| | Mediastinal Diseases | 1 | 2007 | 10 | 0.280 |
Why?
| | Carcinoid Tumor | 1 | 2007 | 26 | 0.280 |
Why?
| | Melanoma | 1 | 2014 | 760 | 0.270 |
Why?
| | Neuroblastoma | 8 | 2010 | 160 | 0.270 |
Why?
| | Parotid Gland | 7 | 1999 | 23 | 0.260 |
Why?
| | Ubiquitins | 4 | 2000 | 36 | 0.240 |
Why?
| | Sarcoidosis | 1 | 2007 | 159 | 0.240 |
Why?
| | Humans | 60 | 2024 | 137585 | 0.240 |
Why?
| | Cell Division | 6 | 2000 | 794 | 0.240 |
Why?
| | Sphingosine | 1 | 2025 | 46 | 0.230 |
Why?
| | Lysophospholipids | 1 | 2025 | 80 | 0.220 |
Why?
| | Mitochondria, Heart | 1 | 2025 | 102 | 0.220 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2025 | 135 | 0.220 |
Why?
| | Italy | 5 | 2014 | 110 | 0.210 |
Why?
| | Perfusion | 1 | 2025 | 213 | 0.210 |
Why?
| | Lymphatic Diseases | 2 | 2009 | 22 | 0.210 |
Why?
| | Finasteride | 3 | 2008 | 35 | 0.210 |
Why?
| | Myocardial Contraction | 1 | 2025 | 341 | 0.210 |
Why?
| | Image-Guided Biopsy | 2 | 2012 | 39 | 0.200 |
Why?
| | Cell Transplantation | 3 | 1997 | 37 | 0.200 |
Why?
| | Middle Aged | 23 | 2024 | 33479 | 0.200 |
Why?
| | Prognosis | 6 | 2019 | 4030 | 0.190 |
Why?
| | Major Histocompatibility Complex | 5 | 1990 | 227 | 0.190 |
Why?
| | Urinary Bladder | 2 | 2014 | 183 | 0.180 |
Why?
| | Prostate-Specific Antigen | 7 | 2020 | 162 | 0.180 |
Why?
| | Antigens, Polyomavirus Transforming | 3 | 1998 | 18 | 0.180 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2021 | 25 | 0.180 |
Why?
| | Seminoma | 1 | 2021 | 20 | 0.180 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1738 | 0.170 |
Why?
| | Graft Rejection | 8 | 1990 | 624 | 0.170 |
Why?
| | Lymph Nodes | 4 | 2015 | 491 | 0.170 |
Why?
| | Diagnosis, Differential | 6 | 2015 | 1483 | 0.170 |
Why?
| | Biomarkers, Tumor | 3 | 2020 | 1276 | 0.170 |
Why?
| | Teratoma | 1 | 2021 | 114 | 0.170 |
Why?
| | Testicular Neoplasms | 1 | 2021 | 110 | 0.160 |
Why?
| | Imaging, Three-Dimensional | 2 | 2015 | 580 | 0.160 |
Why?
| | H-2 Antigens | 4 | 1992 | 115 | 0.160 |
Why?
| | Pyrroles | 2 | 2013 | 213 | 0.160 |
Why?
| | Support Vector Machine | 2 | 2016 | 38 | 0.150 |
Why?
| | Islets of Langerhans Transplantation | 5 | 1992 | 64 | 0.150 |
Why?
| | Liver Cirrhosis, Experimental | 1 | 2019 | 11 | 0.150 |
Why?
| | Perilipin-2 | 1 | 2019 | 41 | 0.150 |
Why?
| | Heart Transplantation | 1 | 2025 | 754 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2024 | 389 | 0.150 |
Why?
| | Cell Transformation, Viral | 2 | 1997 | 25 | 0.140 |
Why?
| | Antineoplastic Agents | 5 | 2013 | 2129 | 0.140 |
Why?
| | Histocompatibility Antigens | 4 | 1988 | 105 | 0.140 |
Why?
| | Nephrectomy | 3 | 2014 | 169 | 0.140 |
Why?
| | Amyloid beta-Peptides | 5 | 2000 | 220 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2018 | 220 | 0.140 |
Why?
| | Hepatocytes | 1 | 2019 | 220 | 0.140 |
Why?
| | Tumor Burden | 2 | 2017 | 309 | 0.140 |
Why?
| | Indoles | 2 | 2013 | 412 | 0.140 |
Why?
| | Factor X Deficiency | 1 | 1997 | 4 | 0.130 |
Why?
| | Rodenticides | 1 | 1997 | 5 | 0.130 |
Why?
| | Hydatidiform Mole | 1 | 1997 | 4 | 0.130 |
Why?
| | Pregnancy, High-Risk | 1 | 1997 | 14 | 0.130 |
Why?
| | 4-Hydroxycoumarins | 1 | 1997 | 4 | 0.130 |
Why?
| | Colonic Pouches | 1 | 2017 | 15 | 0.130 |
Why?
| | Graft Survival | 5 | 1996 | 535 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 2019 | 333 | 0.130 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1946 | 0.130 |
Why?
| | Maternal Age | 1 | 1997 | 129 | 0.130 |
Why?
| | Genital Neoplasms, Male | 1 | 2016 | 5 | 0.130 |
Why?
| | Granular Cell Tumor | 1 | 2016 | 7 | 0.130 |
Why?
| | HIV Seropositivity | 1 | 1997 | 125 | 0.130 |
Why?
| | alpha-Amylases | 4 | 1995 | 16 | 0.130 |
Why?
| | Scrotum | 1 | 2016 | 27 | 0.130 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2019 | 385 | 0.120 |
Why?
| | Adult | 18 | 2024 | 37929 | 0.120 |
Why?
| | Uterine Neoplasms | 1 | 1997 | 109 | 0.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 279 | 0.120 |
Why?
| | Mice | 24 | 2025 | 17787 | 0.120 |
Why?
| | Blood Coagulation | 1 | 1997 | 255 | 0.110 |
Why?
| | Cystotomy | 1 | 2014 | 4 | 0.110 |
Why?
| | Prostatitis | 1 | 2014 | 18 | 0.110 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2014 | 40 | 0.110 |
Why?
| | Rectal Neoplasms | 1 | 2015 | 149 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 155 | 0.110 |
Why?
| | Animals | 34 | 2025 | 36940 | 0.110 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 56 | 0.110 |
Why?
| | Incidence | 3 | 2014 | 2804 | 0.110 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 840 | 0.110 |
Why?
| | Optics and Photonics | 1 | 2014 | 43 | 0.110 |
Why?
| | Adrenergic beta-Agonists | 2 | 1995 | 134 | 0.100 |
Why?
| | Risk Assessment | 2 | 2020 | 3457 | 0.100 |
Why?
| | Colonic Neoplasms | 1 | 2015 | 258 | 0.100 |
Why?
| | Female | 23 | 2024 | 73304 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 1997 | 252 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 168 | 0.100 |
Why?
| | Neurons | 6 | 1999 | 1590 | 0.100 |
Why?
| | Tumor Cells, Cultured | 8 | 2000 | 955 | 0.100 |
Why?
| | Abortion, Habitual | 1 | 1992 | 5 | 0.100 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2012 | 14 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2017 | 10811 | 0.100 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1992 | 11 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 247 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 4 | 2017 | 2691 | 0.100 |
Why?
| | Culture Media | 4 | 1994 | 165 | 0.100 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2014 | 11 | 0.100 |
Why?
| | Niacinamide | 1 | 2013 | 82 | 0.100 |
Why?
| | Phenylurea Compounds | 1 | 2013 | 97 | 0.100 |
Why?
| | Lymphatic Metastasis | 3 | 2024 | 352 | 0.100 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 267 | 0.090 |
Why?
| | Aged, 80 and over | 7 | 2024 | 7635 | 0.090 |
Why?
| | Immune Tolerance | 2 | 1992 | 363 | 0.090 |
Why?
| | Organ Culture Techniques | 2 | 1992 | 156 | 0.090 |
Why?
| | Angiomyolipoma | 1 | 2011 | 24 | 0.090 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 18 | 0.090 |
Why?
| | Triiodothyronine | 1 | 2011 | 43 | 0.090 |
Why?
| | Immunoglobulin A | 1 | 1992 | 211 | 0.090 |
Why?
| | Sarcoma | 1 | 2013 | 188 | 0.090 |
Why?
| | Immunoglobulin M | 1 | 1992 | 289 | 0.090 |
Why?
| | HIV-1 | 1 | 1997 | 864 | 0.090 |
Why?
| | Thyroxine | 1 | 2011 | 62 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5131 | 0.090 |
Why?
| | Hypothyroidism | 1 | 2011 | 72 | 0.080 |
Why?
| | NF-kappa B | 1 | 2014 | 691 | 0.080 |
Why?
| | Thrombocytopenia | 1 | 1992 | 200 | 0.080 |
Why?
| | Mice, Inbred Strains | 6 | 1992 | 409 | 0.080 |
Why?
| | Antigens | 1 | 1992 | 357 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 242 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 665 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 528 | 0.080 |
Why?
| | Smoking | 3 | 1997 | 1627 | 0.080 |
Why?
| | Rats | 12 | 2000 | 5647 | 0.080 |
Why?
| | Cystitis | 1 | 2009 | 22 | 0.080 |
Why?
| | Organ Size | 3 | 2019 | 477 | 0.080 |
Why?
| | Thrombosis | 1 | 1992 | 371 | 0.070 |
Why?
| | Neurotoxins | 2 | 1998 | 29 | 0.070 |
Why?
| | Cyclosporine | 2 | 2000 | 268 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1990 | 367 | 0.070 |
Why?
| | Referral and Consultation | 2 | 2011 | 786 | 0.070 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2008 | 21 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2008 | 46 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 1992 | 893 | 0.070 |
Why?
| | Cohort Studies | 3 | 2020 | 5742 | 0.070 |
Why?
| | Transplantation Immunology | 1 | 1988 | 34 | 0.070 |
Why?
| | Graft Enhancement, Immunologic | 1 | 1987 | 1 | 0.070 |
Why?
| | Chemoprevention | 1 | 2008 | 92 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2007 | 118 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 3 | 2015 | 3566 | 0.070 |
Why?
| | Minor Histocompatibility Loci | 1 | 1987 | 4 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 4 | 2013 | 390 | 0.070 |
Why?
| | Anticarcinogenic Agents | 1 | 2007 | 77 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 916 | 0.070 |
Why?
| | Kidney Diseases, Cystic | 1 | 2006 | 24 | 0.060 |
Why?
| | Staining and Labeling | 3 | 2013 | 150 | 0.060 |
Why?
| | Risk Factors | 3 | 2019 | 10388 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 6 | 1998 | 2486 | 0.060 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5757 | 0.060 |
Why?
| | Amyloid beta-Protein Precursor | 3 | 2000 | 66 | 0.060 |
Why?
| | Obesity | 1 | 2019 | 2992 | 0.060 |
Why?
| | Transplantation, Homologous | 5 | 1992 | 416 | 0.060 |
Why?
| | Syndrome | 2 | 2021 | 358 | 0.060 |
Why?
| | Cell Line, Transformed | 4 | 1998 | 145 | 0.060 |
Why?
| | Cell Differentiation | 5 | 2000 | 1991 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2253 | 0.060 |
Why?
| | Survival Rate | 2 | 2000 | 1972 | 0.060 |
Why?
| | Dopamine | 2 | 1998 | 303 | 0.050 |
Why?
| | Culture Techniques | 3 | 1990 | 81 | 0.050 |
Why?
| | Alprostadil | 3 | 1999 | 32 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 343 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2024 | 686 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1943 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 889 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2015 | 267 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 404 | 0.050 |
Why?
| | Reproducibility of Results | 3 | 2014 | 3284 | 0.050 |
Why?
| | CD4 Antigens | 2 | 1992 | 141 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 40 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4295 | 0.040 |
Why?
| | Time Factors | 3 | 2000 | 6828 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 133 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 1992 | 173 | 0.040 |
Why?
| | Histiocytic Necrotizing Lymphadenitis | 1 | 1999 | 2 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2006 | 638 | 0.040 |
Why?
| | Aluminum | 1 | 2000 | 42 | 0.040 |
Why?
| | Peptidylprolyl Isomerase | 1 | 1999 | 11 | 0.040 |
Why?
| | Angiolymphoid Hyperplasia with Eosinophilia | 1 | 1999 | 2 | 0.040 |
Why?
| | Parotid Diseases | 1 | 1999 | 5 | 0.040 |
Why?
| | Perineum | 1 | 2019 | 32 | 0.040 |
Why?
| | RNA, Messenger | 6 | 1999 | 2833 | 0.040 |
Why?
| | Adenylyl Cyclases | 2 | 1996 | 87 | 0.040 |
Why?
| | Fetal Tissue Transplantation | 1 | 1998 | 35 | 0.040 |
Why?
| | Prostaglandins | 1 | 1998 | 97 | 0.040 |
Why?
| | Cells, Cultured | 7 | 1998 | 4193 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2015 | 15657 | 0.040 |
Why?
| | Prostaglandins A | 1 | 1998 | 10 | 0.040 |
Why?
| | Radiometry | 1 | 2018 | 50 | 0.040 |
Why?
| | Growth Inhibitors | 1 | 1998 | 43 | 0.040 |
Why?
| | CD8 Antigens | 3 | 1992 | 75 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2018 | 268 | 0.040 |
Why?
| | Lung Neoplasms | 2 | 2009 | 2526 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 72 | 0.030 |
Why?
| | Lung Diseases, Obstructive | 1 | 1997 | 50 | 0.030 |
Why?
| | Adenoma | 1 | 2000 | 230 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2018 | 142 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2019 | 247 | 0.030 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 1997 | 51 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 142 | 0.030 |
Why?
| | Vitamin K 1 | 1 | 1997 | 3 | 0.030 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 1 | 1997 | 16 | 0.030 |
Why?
| | Prothrombin Time | 1 | 1997 | 35 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 1999 | 465 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1997 | 54 | 0.030 |
Why?
| | Point Mutation | 1 | 1997 | 235 | 0.030 |
Why?
| | Adolescent | 6 | 2016 | 21513 | 0.030 |
Why?
| | Isoproterenol | 2 | 1994 | 113 | 0.030 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 1996 | 72 | 0.030 |
Why?
| | Brain | 2 | 1998 | 2668 | 0.030 |
Why?
| | Colon, Ascending | 1 | 2015 | 3 | 0.030 |
Why?
| | Mesencephalon | 1 | 1996 | 66 | 0.030 |
Why?
| | Alzheimer Disease | 2 | 2000 | 560 | 0.030 |
Why?
| | Hysterectomy | 1 | 1997 | 129 | 0.030 |
Why?
| | Bronchi | 1 | 1997 | 260 | 0.030 |
Why?
| | Mouth Mucosa | 1 | 1996 | 92 | 0.030 |
Why?
| | Islets of Langerhans | 3 | 1992 | 803 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 2000 | 343 | 0.030 |
Why?
| | Glioma | 1 | 2000 | 395 | 0.030 |
Why?
| | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 3 | 2000 | 3 | 0.030 |
Why?
| | Corpus Striatum | 1 | 1997 | 167 | 0.030 |
Why?
| | Lymphocytes | 2 | 1988 | 397 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 1996 | 162 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2000 | 890 | 0.030 |
Why?
| | Neoplasms | 1 | 1989 | 2671 | 0.030 |
Why?
| | Prostatic Hyperplasia | 1 | 2015 | 44 | 0.030 |
Why?
| | Adenoma, Pleomorphic | 1 | 1994 | 11 | 0.030 |
Why?
| | Parotid Neoplasms | 1 | 1994 | 16 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2019 | 635 | 0.030 |
Why?
| | Patient Selection | 1 | 2018 | 696 | 0.030 |
Why?
| | Mice, Inbred BALB C | 3 | 1989 | 1272 | 0.030 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.030 |
Why?
| | Wavelet Analysis | 1 | 2014 | 7 | 0.030 |
Why?
| | Atrophy | 1 | 2014 | 184 | 0.030 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 98 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
| | Terbutaline | 1 | 1993 | 8 | 0.030 |
Why?
| | beta-Galactosidase | 1 | 2013 | 78 | 0.030 |
Why?
| | Breeding | 1 | 2013 | 64 | 0.030 |
Why?
| | Needles | 1 | 2014 | 59 | 0.030 |
Why?
| | Dobutamine | 1 | 1993 | 39 | 0.030 |
Why?
| | Glucose | 1 | 2019 | 1020 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 95 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1996 | 500 | 0.030 |
Why?
| | Phenotype | 2 | 2019 | 3196 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 2 | 1992 | 417 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 175 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.030 |
Why?
| | Keratins | 1 | 2013 | 173 | 0.030 |
Why?
| | Organ Specificity | 1 | 2013 | 305 | 0.020 |
Why?
| | Kallikreins | 1 | 2012 | 29 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 193 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 120 | 0.020 |
Why?
| | Parkinson Disease | 1 | 1998 | 493 | 0.020 |
Why?
| | Lymphocyte Activation | 3 | 1992 | 1142 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2014 | 153 | 0.020 |
Why?
| | Health Surveys | 1 | 2014 | 514 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 1996 | 596 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 124 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 522 | 0.020 |
Why?
| | Minor Histocompatibility Antigens | 1 | 1992 | 48 | 0.020 |
Why?
| | Pregnancy | 2 | 1997 | 6763 | 0.020 |
Why?
| | Sex Factors | 2 | 2015 | 2071 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 1991 | 1996 | 0.020 |
Why?
| | Antigens, CD | 1 | 2014 | 521 | 0.020 |
Why?
| | Clone Cells | 3 | 1996 | 265 | 0.020 |
Why?
| | Cell Line | 2 | 1994 | 2847 | 0.020 |
Why?
| | Actins | 1 | 1993 | 416 | 0.020 |
Why?
| | Macrophages | 1 | 2019 | 1547 | 0.020 |
Why?
| | Age Factors | 2 | 2015 | 3295 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1208 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 852 | 0.020 |
Why?
| | Cocarcinogenesis | 1 | 1989 | 14 | 0.020 |
Why?
| | Lymphokines | 1 | 1990 | 131 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 872 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2000 | 89 | 0.020 |
Why?
| | Laparoscopy | 1 | 2014 | 466 | 0.020 |
Why?
| | Inflammation | 2 | 1998 | 2837 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 1009 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1991 | 195 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 614 | 0.020 |
Why?
| | Recurrence | 1 | 1992 | 1060 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 11 | 0.020 |
Why?
| | Beverages | 1 | 1989 | 69 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 978 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 60 | 0.020 |
Why?
| | Interferon-gamma | 2 | 1990 | 789 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 658 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 1992 | 406 | 0.020 |
Why?
| | Interferons | 1 | 1990 | 202 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 1070 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1916 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2057 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2167 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5472 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 294 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 199 | 0.020 |
Why?
| | Cisplatin | 1 | 2009 | 320 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1587 | 0.020 |
Why?
| | Immunologic Memory | 1 | 1990 | 353 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1509 | 0.020 |
Why?
| | Bucladesine | 2 | 1998 | 26 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1989 | 203 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2031 | 0.020 |
Why?
| | Medical History Taking | 1 | 2007 | 117 | 0.020 |
Why?
| | Bias | 1 | 2007 | 218 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 560 | 0.020 |
Why?
| | Endocrine Glands | 1 | 1986 | 15 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 1992 | 708 | 0.020 |
Why?
| | Pedigree | 1 | 2007 | 514 | 0.020 |
Why?
| | Radiography | 1 | 2008 | 822 | 0.020 |
Why?
| | Culture Media, Serum-Free | 2 | 1998 | 48 | 0.020 |
Why?
| | Physicians | 1 | 2014 | 910 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 1985 | 28 | 0.010 |
Why?
| | Cell Survival | 1 | 1988 | 1120 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2475 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1985 | 156 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3412 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3556 | 0.010 |
Why?
| | Early Detection of Cancer | 1 | 2008 | 447 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 13209 | 0.010 |
Why?
| | Testosterone | 1 | 2007 | 409 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1079 | 0.010 |
Why?
| | Cross Reactions | 1 | 1983 | 133 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1983 | 269 | 0.010 |
Why?
| | Alcohol Drinking | 1 | 1989 | 828 | 0.010 |
Why?
| | Colorado | 1 | 2012 | 4565 | 0.010 |
Why?
| | Logistic Models | 1 | 2007 | 2074 | 0.010 |
Why?
| | Lymphocyte Depletion | 2 | 1992 | 135 | 0.010 |
Why?
| | Transfection | 2 | 1994 | 945 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1692 | 0.010 |
Why?
| | Alum Compounds | 1 | 2000 | 22 | 0.010 |
Why?
| | Prospective Studies | 1 | 2012 | 7604 | 0.010 |
Why?
| | Neurites | 1 | 2000 | 48 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 1983 | 696 | 0.010 |
Why?
| | Carotenoids | 1 | 1999 | 43 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2007 | 2828 | 0.010 |
Why?
| | Neck | 1 | 1999 | 101 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 1997 | 26 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 68 | 0.010 |
Why?
| | Codon | 1 | 1997 | 89 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 976 | 0.010 |
Why?
| | Simian virus 40 | 1 | 1996 | 24 | 0.010 |
Why?
| | Transplantation, Heterotopic | 1 | 1996 | 18 | 0.010 |
Why?
| | Butyric Acid | 1 | 1996 | 7 | 0.010 |
Why?
| | Epithelium | 1 | 1997 | 313 | 0.010 |
Why?
| | Oxidopamine | 1 | 1996 | 17 | 0.010 |
Why?
| | Xerostomia | 1 | 1996 | 17 | 0.010 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 1996 | 19 | 0.010 |
Why?
| | Protein Kinase C beta | 1 | 1996 | 21 | 0.010 |
Why?
| | Carbocyanines | 1 | 1996 | 33 | 0.010 |
Why?
| | Phosphopyruvate Hydratase | 1 | 1996 | 26 | 0.010 |
Why?
| | Stereotyped Behavior | 1 | 1996 | 19 | 0.010 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1996 | 26 | 0.010 |
Why?
| | Nestin | 1 | 1996 | 19 | 0.010 |
Why?
| | Exons | 1 | 1997 | 355 | 0.010 |
Why?
| | Intermediate Filament Proteins | 1 | 1996 | 57 | 0.010 |
Why?
| | Proline-Rich Protein Domains | 1 | 1995 | 2 | 0.010 |
Why?
| | Protein Kinase C-delta | 1 | 1996 | 48 | 0.010 |
Why?
| | Muscarinic Agonists | 1 | 1995 | 16 | 0.010 |
Why?
| | Salivary Proteins and Peptides | 1 | 1995 | 14 | 0.010 |
Why?
| | Adrenergic alpha-Agonists | 1 | 1995 | 28 | 0.010 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 1996 | 57 | 0.010 |
Why?
| | Cells, Immobilized | 1 | 1995 | 21 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1992 | 3715 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2000 | 706 | 0.010 |
Why?
| | Butyrates | 1 | 1996 | 61 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 127 | 0.010 |
Why?
| | Methamphetamine | 1 | 1996 | 63 | 0.010 |
Why?
| | Isoenzymes | 1 | 1996 | 304 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 308 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1996 | 261 | 0.010 |
Why?
| | Antibodies, Monoclonal | 2 | 1992 | 1430 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 1996 | 321 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1994 | 257 | 0.010 |
Why?
| | Chronic Disease | 1 | 1999 | 1793 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 1992 | 137 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1670 | 0.010 |
Why?
| | Mice, Nude | 1 | 1994 | 698 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1996 | 956 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1996 | 771 | 0.010 |
Why?
| | Blotting, Western | 1 | 1994 | 1226 | 0.010 |
Why?
| | Plasmids | 1 | 1992 | 363 | 0.010 |
Why?
| | Models, Biological | 2 | 1991 | 1783 | 0.010 |
Why?
| | Mice, Inbred NOD | 1 | 1992 | 601 | 0.010 |
Why?
| | Spleen | 1 | 1992 | 514 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 1991 | 298 | 0.010 |
Why?
| | Interleukin-3 | 1 | 1990 | 25 | 0.010 |
Why?
| | United States | 1 | 2007 | 14841 | 0.010 |
Why?
| | Cohort Effect | 1 | 1989 | 5 | 0.010 |
Why?
| | Cacao | 1 | 1989 | 7 | 0.010 |
Why?
| | Peptides | 1 | 1995 | 985 | 0.000 |
Why?
| | Coffee | 1 | 1989 | 17 | 0.000 |
Why?
| | Tea | 1 | 1989 | 21 | 0.000 |
Why?
| | Flow Cytometry | 1 | 1992 | 1178 | 0.000 |
Why?
| | Interleukin-2 | 1 | 1990 | 455 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1992 | 1096 | 0.000 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1990 | 1242 | 0.000 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1990 | 1091 | 0.000 |
Why?
| | Blood Glucose | 1 | 1992 | 2186 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1989 | 6079 | 0.000 |
Why?
| | Infant | 1 | 1989 | 9465 | 0.000 |
Why?
| | Child, Preschool | 1 | 1989 | 11074 | 0.000 |
Why?
| | Child | 1 | 1989 | 21935 | 0.000 |
Why?
|
|
La Rosa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|